Control of Peroxisome Proliferator-Activated Receptor Fate by the UbiquitinProteasome System

REFERENCES

• Chawla A, Repa J J, Evans R M, Mangelsdorf D J. Nuclear receptors and lipid physiology: Opening the x-files. Science 2001; 294: 1866–1870
   PubMed Web of Science ®Google Scholar
• Aranda A, Pascual A. Nuclear hormone receptors and gene expression. Physiol Rev 2001; 81: 1269–1304
   PubMed Web of Science ®Google Scholar
• Gronemeyer H, Gustafsson J A, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004; 3: 950–964
   PubMed Web of Science ®Google Scholar
• Desvergne B, Wahli W. Peroxisome proliferator-activated receptors: Nuclear control of metabolism. Endocr Rev 1999; 20: 649–688
   PubMed Web of Science ®Google Scholar
• Glass C K, Ogawa S. Combinatorial roles of nuclear receptors in inflammation and immunity. Nat Rev Immunol 2006; 6: 44–55
   PubMed Web of Science ®Google Scholar
• Kersten S, Desvergne B, Wahli W. Roles of ppars in health and disease. Nature 2000; 405: 421–424
   PubMed Web of Science ®Google Scholar
• Nolte R T, Wisely G B, Westin S, Cobb J E, Lambert M H, Kurokawa R, Rosenfeld M G, Willson T M, Glass C K, Milburn M V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998; 395: 137–143
   PubMed Web of Science ®Google Scholar
• Kliewer S A, Umesono K, Noonan D J, Heyman R A, Evans R M. Convergence of 9-cis retinoic acid and peroxisome proliferator signalling pathways through heterodimer formation of their receptors. Nature 1992; 358: 771–774
   PubMed Web of Science ®Google Scholar
• Lefebvre P, Chinetti G, Fruchart J C, Staels B. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest 2006; 116: 571–580
   PubMed Web of Science ®Google Scholar
• Semple R K, Chatterjee V K, O'Rahilly S. PPARγ and human metabolic disease. J Clin Invest 2006; 116: 581–589
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Hu E, Spiegelman B M. Stimulation of adipogenesis in fibroblasts by PPARγ 2, a lipid-activated transcription factor. Cell 1994; 79: 1147–1156
   PubMed Web of Science ®Google Scholar
• Ricote M, Li A C, Willson T M, Kelly C J, Glass C K. The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation. Nature 1998; 391: 79–82
   PubMed Web of Science ®Google Scholar
• Kubota N, Terauchi Y, Miki H, Tamemoto H, Yamauchi T, Komeda K, Satoh S, Nakano R, Ishii C, Sugiyama T, Eto K, Tsubamoto Y, Okuno A, Murakami K, Sekihara H, Hasegawa G, Naito M, Toyoshima Y, Tanaka S, Shiota K, Kitamura T, Fujita T, Ezaki O, Aizawa S, Kadowaki T, et al. PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999; 4: 597–609
   PubMed Web of Science ®Google Scholar
• Schwartz S, Raskin P, Fonseca V, Graveline J F. Effect of troglitazone in insulin-treated patients with type ii diabetes mellitus. Troglitazone and exogenous insulin study group. N Engl J Med 1998; 338: 861–866
   PubMed Web of Science ®Google Scholar
• Michalik L, Desvergne B, Wahli W. Peroxisome-proliferator-activated receptors and cancers: Complex stories. Nat Rev Cancer 2004; 4: 61–70
   PubMed Web of Science ®Google Scholar
• Tontonoz P, Singer S, Forman B M, Sarraf P, Fletcher J A, Fletcher C D, Brun R P, Mueller E, Altiok S, Oppenheim H, Evans R M, Spiegelman B M. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor γ and the retinoid x receptor. Proc Natl Acad Sci USA 1997; 94: 237–241
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Jones D, King F J, DeAngelo D J, Partridge J B, Holden S A, Chen L B, Singer S, Fletcher C, Spiegelman B M. Differentiation and reversal of malignant changes in colon cancer through PPARγ. Nat Med 1998; 4: 1046–1052
   PubMed Web of Science ®Google Scholar
• Sarraf P, Mueller E, Smith W M, Wright H M, Kum J B, Aaltonen L A, de la Chapelle A, Spiegelman B M, Eng C. Loss-of-function mutations in PPARγ associated with human colon cancer. Mol Cell 1999; 3: 799–804
   PubMed Web of Science ®Google Scholar
• Mueller E, Smith M, Sarraf P, Kroll T, Aiyer A, Kaufman D S, Oh W, Demetri G, Figg W D, Zhou X P, Eng C, Spiegelman B M, Kantoff P W. Effects of ligand activation of peroxisome proliferator-activated receptor γ in human prostate cancer. Proc Natl Acad Sci USA 2000; 97: 10990–10995
   PubMed Web of Science ®Google Scholar
• Kroll T G, Sarraf P, Pecciarini L, Chen C J, Mueller E, Spiegelman B M, Fletcher J A. Pax8-PPARγ 1 fusion oncogene in human thyroid carcinoma [corrected]. Science 2000; 289: 1357–1360
   PubMed Web of Science ®Google Scholar
• Lefebvre A M, Chen I, Desreumaux P, Najib J, Fruchart J C, Geboes K, Briggs M, Heyman R, Auwerx J. Activation of the peroxisome proliferator-activated receptor γ promotes the development of colon tumors in c57bl/6j-apcmin/+ mice. Nat Med 1998; 4: 1053–1057
   PubMed Web of Science ®Google Scholar
• Kliewer S A, Forman B M, Blumberg B, Ong E S, Borgmeyer U, Mangelsdorf D J, Umesono K, Evans R M. Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355–7359
   PubMed Web of Science ®Google Scholar
• Braissant O, Foufelle F, Scotto C, Dauca M, Wahli W. Differential expression of peroxisome proliferator-activated receptors (PPARs): Tissue distribution of PPAR-α,-β, and-γ in the adult rat. Endocrinology 1996; 137: 354–366
   PubMed Web of Science ®Google Scholar
• Michalik L, Wahli W. Involvement of PPAR nuclear receptors in tissue injury and wound repair. J Clin Invest 2006; 116: 598–606
   PubMed Web of Science ®Google Scholar
• Barish G D, Narkar V A, Evans R M. PPARδ : A dagger in the heart of the metabolic syndrome. J Clin Invest 2006; 116: 590–597
   PubMed Web of Science ®Google Scholar
• He T C, Chan T A, Vogelstein B, Kinzler K W. Ppardelta is an apc-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999; 99: 335–345
   PubMed Web of Science ®Google Scholar
• Shao J, Sheng H, DuBois R N. Peroxisome proliferator-activated receptors modulate k-ras-mediated transformation of intestinal epithelial cells. Cancer Res 2002; 62: 3282–3288
   PubMed Web of Science ®Google Scholar
• Gupta R A, Tan J, Krause W F, Geraci M W, Willson T M, Dey S K, DuBois R N. Prostacyclin-mediated activation of peroxisome proliferator-activated receptor delta in colorectal cancer. Proc Natl Acad Sci USA 2000; 97: 13275–13280
   PubMed Web of Science ®Google Scholar
• Jarvis M C, Gray T J, Palmer C N. Both PPARγ and PPARδ influence sulindac sulfide-mediated p21waf1/cip1 upregulation in a human prostate epithelial cell line. Oncogene 2005; 24: 8211–8215
   PubMed Web of Science ®Google Scholar
• Gupta R A, Dubois R N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer 2001; 1: 11–21
   PubMed Web of Science ®Google Scholar
• Park B H, Vogelstein B, Kinzler K W. Genetic disruption of ppardelta decreases the tumorigenicity of human colon cancer cells. Proc Natl Acad Sci USA 2001; 98: 2598–2603
   PubMed Web of Science ®Google Scholar
• Hatae T, Wada M, Yokoyama C, Shimonishi M, Tanabe T. Prostacyclin-dependent apoptosis mediated by PPARδ. J Biol Chem 2001; 276: 46260–46267
   PubMed Web of Science ®Google Scholar
• Ciechanover A, Orian A, Schwartz A L. Ubiquitin-mediated proteolysis: Biological regulation via destruction. Bioessays 2000; 22: 442–451
   PubMed Web of Science ®Google Scholar
• Koegl M, Hoppe T, Schlenker S, Ulrich H D, Mayer T U, Jentsch S. A novel ubiquitination factor, e4, is involved in multiubiquitin chain assembly. Cell 1999; 96: 635–644
   PubMed Web of Science ®Google Scholar
• Baek K H. Conjugation and deconjugation of ubiquitin regulating the destiny of proteins. Exp Mol Med 2003; 35: 1–7
   PubMed Web of Science ®Google Scholar
• Terrell J, Shih S, Dunn R, Hicke L. A function for monoubiquitination in the internalization of a G protein-coupled receptor. Mol Cell 1998; 1: 193–202
   PubMed Web of Science ®Google Scholar
• Dennis A P, Lonard D M, Nawaz Z, O'Malley B W. Inhibition of the 26s proteasome blocks progesterone receptor-dependent transcription through failed recruitment of rna polymerase ii. J Steroid Biochem Mol Biol 2005; 94: 337–346
   PubMed Web of Science ®Google Scholar
• Spence J, Gali R R, Dittmar G, Sherman F, Karin M, Finley D. Cell cycle-regulated modification of the ribosome by a variant multiubiquitin chain. Cell 2000; 102: 67–76
   PubMedGoogle Scholar
• Goldknopf I L, Taylor C W, Baum R M, Yeoman L C, Olson M O, Prestayko A W, Busch H. Isolation and characterization of protein A24, a “histone-like” non-histone chromosomal protein. J Biol Chem 1975; 250: 7182–7187
   PubMed Web of Science ®Google Scholar
• Muratani M, Tansey W P. How the ubiquitin-proteasome system controls transcription. Nat Rev Mol Cell Biol 2003; 4: 192–201
   PubMed Web of Science ®Google Scholar
• Lee K B, Wang D, Lippard S J, Sharp P A. Transcription-coupled and DNA damage-dependent ubiquitination of RNA polymerase ii in vitro. Proc Natl Acad Sci USA 2002; 99: 4239–4244
   PubMed Web of Science ®Google Scholar
• Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 1998; 67: 425–479
   PubMed Web of Science ®Google Scholar
• Syvala H, Vienonen A, Zhuang Y H, Kivineva M, Ylikomi T, Tuohimaa P. Evidence for enhanced ubiquitin-mediated proteolysis of the chicken progesterone receptor by progesterone. Life Sci 1998; 63: 1505–1512
   PubMed Web of Science ®Google Scholar
• Alarid E T, Bakopoulos N, Solodin N. Proteasome-mediated proteolysis of estrogen receptor: A novel component in autologous down-regulation. Mol Endocrinol 1999; 13: 1522–1534
   PubMed Web of Science ®Google Scholar
• Dace A, Zhao L, Park K S, Furuno T, Takamura N, Nakanishi M, West B L, Hanover J A, Cheng S. Hormone binding induces rapid proteasome-mediated degradation of thyroid hormone receptors. Proc Natl Acad Sci USA 2000; 97: 8985–8990
   PubMed Web of Science ®Google Scholar
• Lonard D M, Nawaz Z, Smith C L, O'Malley B W. The 26S proteasome is required for estrogen receptor-α and coactivator turnover and for efficient estrogen receptor-α transactivation. Mol Cell 2000; 5: 939–948
   PubMed Web of Science ®Google Scholar
• Deroo B J, Archer T K. Proteasome inhibitors reduce luciferase and β-galactosidase activity in tissue culture cells. J Biol Chem 2002; 277: 20120–20123
   PubMed Web of Science ®Google Scholar
• Kopf E, Plassat J L, Vivat V, de The H, Chambon P, Rochette-Egly C. Dimerization with retinoid x receptors and phosphorylation modulate the retinoic acid-induced degradation of retinoic acid receptors α and γ through the ubiquitin-proteasome pathway. J Biol Chem 2000; 275: 33280–33288
   PubMed Web of Science ®Google Scholar
• Rochette-Egly C. Dynamic combinatorial networks in nuclear receptor-mediated transcription. J Biol Chem 2005; 280: 32565–32568
   PubMed Web of Science ®Google Scholar
• Pickart C M. Targeting of substrates to the 26S proteasome. FASEB J 1997; 11: 1055–1066
   PubMed Web of Science ®Google Scholar
• Blanquart C, Barbier O, Fruchart J C, Staels B, Glineur C. Peroxisome proliferator-activated receptor alpha (PPARα) turnover by the ubiquitin-proteasome system controls the ligand-induced expression level of its target genes. J Biol Chem 2002; 277: 37254–37259
   PubMed Web of Science ®Google Scholar
• Hauser S, Adelmant G, Sarraf P, Wright H M, Mueller E, Spiegelman B M. Degradation of the peroxisome proliferator-activated receptor γ is linked to ligand-dependent activation. J Biol Chem 2000; 275: 18527–18533
   PubMed Web of Science ®Google Scholar
• Nawaz Z, Lonard D M, Smith C L, Lev-Lehman E, Tsai S Y, Tsai M J, O'Malley B W. The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. Mol Cell Biol 1999; 19: 1182–1189
   PubMed Web of Science ®Google Scholar
• Webster J C, Jewell C M, Bodwell J E, Munck A, Sar M, Cidlowski J A. Mouse glucocorticoid receptor phosphorylation status influences multiple functions of the receptor protein. J Biol Chem 1997; 272: 9287–9293
   PubMed Web of Science ®Google Scholar
• Hirotani M, Tsukamoto T, Bourdeaux J, Sadano H, Osumi T. Stabilization of peroxisome proliferator-activated receptor α by the ligand. Biochem Biophys Res Commun 2001; 288: 106–110
   PubMed Web of Science ®Google Scholar
• Dennis A P, Haq R U, Nawaz Z. Importance of the regulation of nuclear receptor degradation. Front Biosci 2001; 6: D954–959
   PubMed Web of Science ®Google Scholar
• Read L D, Snider C E, Miller J S, Greene G L, Katzenellenbogen B S. Ligand-modulated regulation of progesterone receptor messenger ribonucleic acid and protein in human breast cancer cell lines. Mol Endocrinol 1988; 2: 263–271
   PubMedGoogle Scholar
• Zhu J, Gianni M, Kopf E, Honore N, Chelbi-Alix M, Koken M, Quignon F, Rochette-Egly C, de The H. Retinoic acid induces proteasome-dependent degradation of retinoic acid receptor alpha (RARα) and oncogenic RARα fusion proteins. Proc Natl Acad Sci USA 1999; 96: 14807–14812
   PubMed Web of Science ®Google Scholar
• Li X Y, Boudjelal M, Xiao J H, Peng Z H, Asuru A, Kang S, Fisher G J, Voorhees J J. 1,25-Dihydroxyvitamin D3 increases nuclear vitamin D3 receptors by blocking ubiquitin/proteasome-mediated degradation in human skin. Mol Endocrinol 1999; 13: 1686–1694
   PubMedGoogle Scholar
• Yeap B B, Krueger R G, Leedman P J. Differential posttranscriptional regulation of androgen receptor gene expression by androgen in prostate and breast cancer cells. Endocrinology 1999; 140: 3282–3291
   PubMed Web of Science ®Google Scholar
• Perissi V, Aggarwal A, Glass C K, Rose D W, Rosenfeld M G. A corepressor/coactivator exchange complex required for transcriptional activation by nuclear receptors and other regulated transcription factors. Cell 2004; 116: 511–526
   PubMed Web of Science ®Google Scholar
• Lipford J R, Deshaies R J. Diverse roles for ubiquitin-dependent proteolysis in transcriptional activation. Nat Cell Biol 2003; 5: 845–850
   PubMed Web of Science ®Google Scholar